UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or Other Jurisdiction of |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
|
Incorporation or Organization) |
|
|
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, include area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading |
Name of each exchange on which registered |
|
||
|
Symbol(s) |
|
||||
|
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07Submission of Matters to a Vote of Security Holders.
Crinetics Pharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders on June 22, 2021. The following is a brief description of each matter voted upon at the meeting and the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as applicable.
|
|
1. |
The election of two directors to serve as Class III directors for a three-year term to expire at the 2024 annual meeting of stockholders. The following two Class III directors were re-elected by the votes indicated: |
|
|
|
For |
Withheld |
Broker Non-Votes |
||
|
Camille Bedrosian, M.D. |
25,859,471 |
|
4,554,351 |
|
3,205,675 |
|
Wendell Wierenga, Ph.D. |
30,379,916 |
|
33,906 |
|
3,205,675 |
|
|
2. |
The ratification of the selection of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021. The selection was ratified by the votes indicated: |
|
|
For |
|
Against |
|
Abstain |
|
Broker Non-Votes |
|
33,616,813 |
|
83 |
|
2,601 |
|
0 |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Crinetics Pharmaceuticals, Inc. |
|
|
Date: June 23, 2021 |
By: |
/s/ R. Scott Struthers, Ph.D. |
|
|
|
R. Scott Struthers, Ph.D. |
|
|
|
President and Chief Executive Officer |
2
Document and Entity Information |
Jun. 22, 2021 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Jun. 22, 2021 |
| Entity Registrant Name | Crinetics Pharmaceuticals, Inc. |
| Entity Central Index Key | 0001658247 |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | true |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-38583 |
| Entity Tax Identification Number | 26-3744114 |
| Entity Address, Address Line One | 10222 Barnes Canyon Road |
| Entity Address, Address Line Two | Bldg. #2 |
| Entity Address, City or Town | San Diego |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 92121 |
| City Area Code | (858) |
| Local Phone Number | 450-6464 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, par value $0.001 per share |
| Trading Symbol | CRNX |
| Security Exchange Name | NASDAQ |
-8?20$3;8T.P6BP^0"X99K>]9!:G